Opaleye Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Opaleye Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-205,381	Closed	-$6.98M	–	48
2021 Q3	$6.98M	Hold	205,381	–	–	1.3%	26
2021 Q2	$7.52M	Sell	205,381 -16,619	-7%	-$643K	1.25%	26
2021 Q1	$9.95M	Hold	222,000	–	–	1.46%	18
2020 Q4	$12.7M	Hold	222,000	–	–	1.66%	17
2020 Q3	$11.4M	Hold	222,000	–	–	2.23%	14
2020 Q2	$13.1M	Hold	222,000	–	–	2.64%	14
2020 Q1	$9.14M	Sell	222,000 -2,500	-1%	-$139K	2.42%	15
2019 Q4	$14M	Sell	224,500 -5,500	-2%	-$261K	2.74%	14
2019 Q3	$7.81M	Sell	230,000 -80,000	-26%	-$2.37M	2.82%	14
2019 Q2	$6.99M	Sell	310,000 -30,000	-9%	-$702K	2.13%	20
2019 Q1	$7.89M	Hold	340,000	–	–	2.19%	18
2018 Q4	$7.14M	Sell	340,000 -80,000	-19%	-$1.97M	2.66%	8
2018 Q3	$16.3M	Hold	420,000	–	–	4.14%	6
2018 Q2	$16.5M	Buy	420,000 +55,000	+15%	+$1.62M	4.28%	7
2018 Q1	$7.31M	Buy	+365,000	New	+$9.24M	2.09%	14
2017 Q4	–	Sell	-217,000	Closed	-$4.12M	–	43
2017 Q3	$4.12M	Buy	+217,000	New	+$3.98M	1.46%	22

Other funds holding DCPH

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Opaleye Management's DCPH Position: Q4 2021 in Review

Opaleye Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2021, closing a stake of 205,381 shares — an estimated $6.98M sold.

Opaleye Management first reported a position in DCPH in Q3 2017 and held it in 16 quarters. The position peaked at $16.5M in Q2 2018. 140 funds tracked by Wall St. Rank hold DCPH as of Q4 2021.

Opaleye Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Opaleye Management sold 205,381 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $6.98M.
Opaleye Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 16 quarters.
Opaleye Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $16.5M in Q2 2018.
140 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Opaleye Management's 13F filing for Q4 2021, filed 14 Feb 2022.